Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | HHAT | Q5VTY9 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LHCGR | P22888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8026128 | 0.80 | DRD1 (0.52) | DRD1HHATKMT2AMAPK1NPSR1 | |
| SCHEMBL8028051 | 0.80 | DRD1 (0.52) | DRD1HHATKMT2AMAPK1NPSR1 | |
| SCHEMBL1863899 | 0.80 | DRD1 (0.52) | DRD1HHATKMT2AMAPK1NPSR1 | |
| SCHEMBL28449155 | 0.76 | KMT2A (0.40) | DRD1HHATKMT2A | |
| SCHEMBL29970524 | 0.75 | SMN1; SMN2 (0.37) | DRD1HHATKMT2AMAPK1 | |
| SCHEMBL22044650 | 0.74 | KMT2A (0.51) | DRD1HHATKMT2A | |
| SCHEMBL29971027 | 0.74 | SMN1; SMN2 (0.36) | DRD1HHATKMT2A | |
| SCHEMBL14096426 | 0.72 | DRD1 (0.53) | DRD1KMT2AMAPK1NPSR1LHCGR | |
| SCHEMBL21465733 | 0.72 | DRD1 (0.60) | DRD1HHAT | |
| SCHEMBL30878500 | 0.72 | DRD1 (0.60) | DRD1HHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746444-B1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-27 | — | — | EP | disclosed |
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | Janssen Sciences Ireland Unlimited Company Co Cork, IE (IE) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | ACE, ACE2, PTBP1 | DRD1 3977/4885HHAT 2436/4885KMT2A 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.